Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model

BACKGROUND: Infliximab (IFX), a TNF-α blocking chimeric monoclonal antibody, induces clinical response and mucosal healing in patients with inflammatory bowel disease (IBD). However, systemic administration of this agent causes unwanted side effects. Oral delivery of antibody therapeutics might be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jung Min, Kim, Da Hye, Park, Hyo Jeong, Ma, Hyun Woo, Park, I Seul, Son, Mijeong, Ro, So Youn, Hong, Seokmann, Han, Hyo Kyung, Lim, Soo Jeong, Kim, Seung Won, Cheon, Jae Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493402/
https://www.ncbi.nlm.nih.gov/pubmed/32933548
http://dx.doi.org/10.1186/s12951-020-00693-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493402/
https://www.ncbi.nlm.nih.gov/pubmed/32933548
http://dx.doi.org/10.1186/s12951-020-00693-4

Ejemplares similares